Most drugs work only on a fraction of the patients, leading to high failure rates of clinical trials and poor efficacy of drugs when delivered to patients. This calls for precision medicine solutions that match the right patient to the right treatment. Combining deep molecular profiling and our unbiased and robust AI discovery platform ScaiVision leads to highly accurate biomarkers and clinically-relevant insights.
90% of clinical trials fail
50% of failed trials lack clinical efficacy
90 / 50
Actionable biomarkers
90% of approved drugs work only in
50% of the patients
We discover clinically-relevant biomarkers with single-cell analytics and AI
Disease diagnosis
Identify novel biomarkers for an early disease diagnosis
Patient stratification
Identify patients with higher chance to respond to treatment
Mode of Action
Understand the effect on patient’s immune response
Patient monitoring
Identify prognostic and predictive biomarkers
12 successful discovery projects
1000+ single cell samples analyzed
50 Billion data points
Single-cell resolution
We harness the richness of single-cell multiomics data to explain complex biological processes
Artificial Intelligence
We apply AI for unbiased, innovative, sensitive, and integrative multiomics data analysis
Biomarker discovery
We deliver translatable biomarker signatures related to therapy response, diagnosis or disease severity
Faster time-to-insights for accelerated biomarker discovery
Sensitive and specific biomarker discovery to identify clinical biomarkers not achievable by conventional analytics
Fully transparent and explainable results allow the translation of biomarker discoveries into simple, affordable clinical assays
Demonstrated best-in-class AI, ensuring superior robustness and reliability of biomarker discoveries
The discovery and development of biomarkers for precision medicine using single-cell data and AI fully exploits the power of cutting-edge technologies in translational research. We are paving the way for the development of new life-saving diagnostics and next-generation therapeutics for complex diseases.
Meghan Verschoor
Associate Director, Data Science in Clinical and Translational Medicine at Turnstone Biologics
Thomas Mehrling
MD PhD, CEO of MaxiVAX
Prof. Dr Michael Mueller
Leading Clinician in Women’s Health & Scientific Advisor
Pascal Koenig
Entrepreneur & Chairman of the Board of Directors
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...